Small Molecules

Small Molecules
Product Description

Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.

CESS® is a bottom-up method of recrystallization that works by controlling the solubility of an API in supercritical carbon dioxide (scCO2). The use of scCO2 permits a green particle engineering process with pharmaceutical CO2 that is free from excipients and organic solvents. CESS® represents a significant improvement over previous supercritical technologies due to the employment of controlled mass transfer, flow and pressure reduction.

Benefits of CESS®

Controlled particle shape

Our nanoforming process can control the shape of particles, leading to greater uniformity.


Controlled particle size

Our technology can produce nanoparticles as small as 10 nm. Smaller particles have greater active surface areas, which permits an increased rate of dissolution.


Controlled polymorphism

Polymorphic purity tests have shown that stable single polymorphs can be produced with defined process parameters enabling polymorphic control.

Read more Show less

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other
View company profile

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other
View company profile

More Products from Nanoform Finland Oy (3)

  • AI Drug Candidate Screening

    Product AI Drug Candidate Screening

    Our STARMAP® 2.0 platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered nanoforming and that exhibit optimal production characteristics.

    When existing data alone is not sufficient for generating specific pr...
  • Biologics

    Product Biologics

    Why have we developed our bio nanoparticle technology?

    The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes,...
  • Formulations

    Product Formulations

    We understand that speed is of the essence when working to deliver a life-changing drug to market. Our experienced clinical formulation development team can support formulation development across a vast range of dosage forms – including oral, ophthalmic and transdermal formulations, as well as injectables,...

Nanoform Finland Oy resources (4)

  • Nanoform brochure

    Brochure Nanoform brochure

    NanoImprove the Performance of Your Formulations Small and Large Molecule Formulations Across the Product Life Cycle.NanoImprove Small Molecules
    NanoImprove Large Molecules
    NanoImprove the Performance of Your BioFormulations With NanoParticles by Design
    Nanoforming Success Accelerated by Proprietary AI Technology STARMAP® Drives Predictions of NanoImprovement Success
  • (b)(2) or not to be, that is the question* Strategies for patient-centric differentiation through the USFDA 505(b)(2) pathway

    Whitepaper "(b)(2) or not to be, that is the question* Strategies for patient-centric differentiation through the USFDA 505(b)(2) pathway

    USFDA 505(b)(2) submissions can be advantageous because they can often lead to faster routes to approval when compared to traditional development pathways while creating new, differentiated products with commercial value. Jamie Unwin, Commercial Insight Officer at Nanoform, sat down with Timothy Pang, Executive Director, Pharma Consulting at Informa Pharma Custom Intelligence to discuss unique performance insights from the last three years for key molecules approved by this pathway, and to reflect on how patient-centric drug development has generated commercial value. Further, they discussed their view on the future direction of the industry with regards to the adoption of 505(b)(2) approaches, and the key technological advances that can empower these. Read on to find out more.
  • Sustainability ebook

    Brochure Sustainability ebook

    small is green Small empowers your sustainability goals
  • Nanoformed API: A Superior Alternative to Solid Dispersions

    Whitepaper Nanoformed API: A Superior Alternative to Solid Dispersions

    Cutting-edge nanotechnology is now emerging, with strong clinical evidence, as an alternative to amorphous solid dispersion (ASD), able to not only address bioavailability challenges but also deliver higher drug loads in much more patientfriendly formats with fewer and smaller pills and easier regimens.